Stock Market Reviews

ARDX (Ardelyx, Inc.) News

Get the latest news, insights, and market updates on ARDX (Ardelyx, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Why Ardelyx (ARDX) Is Up 20.2% After Positive IBSRELA Patient Data at ACG 2025 Conference
  In late October 2025, Ardelyx presented new real-world and clinical data for its IBSRELA (tenapanor) therapy at the American College of Gastroenterology’s Annual Meeting, showing high patient satisfaction and significant improvement in irritable bowel syndrome with constipation symptoms. The studies also indicated that IBSRELA may help reduce healthcare resource use, with patients reporting fewer gastrointestinal visits and lower portal messaging following therapy initiation. We'll examine...
  Nov 2, 2025 - $ARDX
• Ardelyx Inc (ARDX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Market Challenges
  Ardelyx Inc (ARDX) reports a 15% YoY revenue increase, driven by IBSRELA's impressive performance, while navigating competitive pressures and financial hurdles.
  Oct 31, 2025 - $ARDX
• Ardelyx: Q3 Earnings Snapshot
  WALTHAM, Mass. AP) — Ardelyx Inc. ARDX) on Thursday reported a loss of $969,000 in its third quarter.
  Oct 30, 2025 - $ARDX
• Ardelyx (ARDX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
  While the top- and bottom-line numbers for Ardelyx (ARDX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
  Oct 30, 2025 - $ARDX
• Ardelyx (ARDX) Reports Break-Even Earnings for Q3
  Ardelyx (ARDX) delivered earnings and revenue surprises of +100.00% and +10.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Oct 30, 2025 - $ARDX
• Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
  Q3 2025 product revenue of $105.5 million reflects 15% year-over-year growth IBSRELA® Q3 revenue of $78.2 million reflects 92% year-over-year growth; IBSRELA guidance raised, 2025 revenue expected to be between $270-275 million XPHOZAH® Q3 revenue of $27.4 million, up 9% compared to Q2 2025 Company announces pipeline program for next-generation NHE3 inhibitor; Potential application across multiple therapeutic areas Conference call scheduled for 4:30 PM Eastern Time WALTHAM, Mass., Oct. 30, 2025
  Oct 30, 2025 - $ARDX
• Ardelyx Presents Data that Continues to Support the Benefits of IBSRELA® (tenapanor) at the American College of Gastroenterology’s 2025 Annual Meeting
  IBSRELA patients reported treatment satisfaction in real-world survey Post-hoc analysis of T3MPO-1 and T3MPO-2 studies demonstrates effectiveness of IBSRELA in reducing abdominal bloating for patients with IBS-C Analysis of electronic health records suggests IBSRELA may reduce burden to healthcare system WALTHAM, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-cla
  Oct 28, 2025 - $ARDX
• Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology’s Kidney Week
  WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced upcoming data presentations supporting XPHOZAH® (tenapanor) at the American Society of Nephrology’s Kidney Week, to be held November 5-9, 2025, in Houston. XPHOZAH, the first and only phosphate absorption inhibitor (PAI), is approved
  Oct 21, 2025 - $ARDX
• 2 Overlooked Stocks to Snap Up in 2025
  While much of Wall Street’s attention in 2025 centers around AI names, two under-the-radar companies are quietly getting stronger.
  Oct 16, 2025 - $ARDX
• Where Does Ardelyx Stand After Its Recent 24% Share Price Drop?
  Trying to decide what your next move should be with Ardelyx stock? You’re definitely not alone. Ardelyx has been on the radar for plenty of investors, with some eye-catching ups and downs. Maybe you’ve been watching the market’s mood swings lately, or maybe you’re just now curious after hearing others talk about the company’s wild 238.5% climb in the last three years. Even with that impressive long-term gain, recent months have been rough: Ardelyx dropped 24.2% over the last 30 days and has...
  Oct 14, 2025 - $ARDX